CEBPA Methylation as a Prognostic Biomarker in Adult Patients with De Novo AML.

被引：0
|
作者：
Chen, Hsin-Yu [1 ]
Lin, Tsung-Chin [1 ]
Chou, Wen-Chien [1 ]
Hou, Hsin-An [1 ]
Tien, Hwei-Fang [1 ]
Lin, Liang-In [1 ]
机构：
[1] Natl Taiwan Univ, Taipei 10764, Taiwan
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：628 / 628
页数：1
相关论文
共 50 条
  • [21] Detection of minimal residual disease with double flow cytometry - Atypical antigen combinations in patients with de novo AML.
    Plata, E
    ChoremiPapadopoulou, H
    Viglis, V
    Viniou, N
    Konstantopoulos, K
    Meletis, J
    Loukopoulos, D
    Yataganas, X
    BLOOD, 1996, 88 (10) : 2235 - 2235
  • [22] Combination HDACi and mTOR inhibitor therapy in poor-risk de novo and refractory elderly patients with AML.
    Sandilya, Vijay Krishna
    Ghai, Vikas
    Sharma, Kamal
    Abbi, Kamal Kant Singh
    Epner, Elliot E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Comparison of functional differences in haemopoietic growth factor receptors in de novo and secondary AML.
    Smith, MA
    Pallister, CJ
    Singer, CRJ
    Smith, JG
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 32 - 32
  • [24] Prognostic factors predicting survival in de novo AML patients requiring intensive care
    Schellongowski, Peter
    Staudinger, Thomas
    Laczika, Klaus
    Locker, Gottfried
    Bojic, Andja
    Jaeger, Ulrich
    Valent, Peter
    Sperr, Wolfgang R.
    BLOOD, 2007, 110 (11) : 841A - 841A
  • [25] Extramedullary leukemia predicts unfavorable prognosis in children with AML: Experience of the AML-BFM studies in 974 children with de novo AML.
    Creutzig, U
    Reinhardt, D
    Ritter, J
    Schrappe, M
    Teigler-Schlegel, A
    Zimmermann, M
    BLOOD, 2001, 98 (11) : 719A - 719A
  • [26] Reproducibility and Prognostic Significance of Morphologic Dysplasia in De Novo AML
    Weinberg, Olga
    Pozdnyakova, Olga
    Campigotto, Federico
    DeAngelo, Daniel
    Stone, Richard
    Neuberg, Donna
    Hasserjian, Robert
    LABORATORY INVESTIGATION, 2015, 95 : 385A - 386A
  • [27] De novo AML with dysplastic hematopoiesis: Cytogenetic and prognostic significance
    Gahn, B
    Haase, D
    Unterhalt, M
    Drescher, M
    Schoch, C
    Fonatsch, C
    Terstappen, LWMM
    Hiddemann, W
    Buchner, T
    Bennett, JM
    Wormann, B
    LEUKEMIA, 1996, 10 (06) : 946 - 951
  • [28] Reproducibility and Prognostic Significance of Morphologic Dysplasia in De Novo AML
    Weinberg, Olga
    Pozdnyakova, Olga
    Campigotto, Federico
    DeAngelo, Daniel
    Stone, Richard
    Neuberg, Donna
    Hasserjian, Robert
    MODERN PATHOLOGY, 2015, 28 : 385A - 386A
  • [29] A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML
    Luskin, Marlise R.
    Gimotty, Phyllis
    Smith, Catherine
    Loren, Alison
    Figueroa, Maria
    Harrison, Jenna
    Sun, Zhuoxin
    Tallman, Martin S.
    Paietta, Elisabeth
    Litzow, Mark R.
    Levine, Ross L.
    Fernandez, Hugo F.
    Luger, Selina
    Carroll, Martin
    Master, Stephen
    Wertheim, Gerald
    BLOOD, 2015, 126 (23)
  • [30] Dissimilar effects of caspase 2 and caspase 3 levels in adults with de novo ALL and AML.
    Faderl, S
    Thall, PF
    Kantarjian, HM
    Talpaz, M
    Estey, E
    Thomas, D
    Andreeff, M
    Kornblau, S
    Harris, D
    Van, Q
    Estrov, Z
    BLOOD, 1999, 94 (10) : 68A - 68A
12345